Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Biologic antagonists to tumor necrosis factor alpha (TNF- α) are effective medications and have become well established in the treatment of both Crohn's disease and ulcerative colitis.
|
28095262 |
2017 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease.
|
29286110 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that a disintegrin and metalloproteinase-17 (ADAM17), a main sheddase for tumor necrosis factor (TNF)-α, is essential for defensive epithelial properties against UC by promoting epithelial cell growth and goblet cell differentiation in mouse and human.
|
27077118 |
2016 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.
|
31790426 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BT-11 significantly decreases interferon gamma positive (IFNγ+) and tumor necrosis factor alpha positive (TNFα+) cluster of differentiation 4 positive (CD4+) T cells and increases forkhead box P3 positive (FOXP3+) CD4+ T cells in colonic lamina propria mononuclear cells from patients with CD and patients with UC at concentrations of 0.01 µM when treated ex vivo.
|
31077582 |
2020 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Some studies have reported that proinflammatory polymorphisms in tumor necrosis factor-alpha-308 (TNF-alpha-308) gene promoter (substitution G-->A, designated as TNF1 and TNF2) is associated with increased UC risk.
|
18827481 |
2008 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that one of the genes responsible for UC may be the TNF gene, or an adjacent gene, and that TNFRSF1B gene polymorphisms contribute greatly to the increased onset risk of CD and to the disease behavior.
|
11904678 |
2002 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with that in the DSS group, FMT ameliorated the severity of inflammation due to ulcerative colitis in mice, which was accompanied by a significantly decreased MPO activity, reduced levels of TNF-α and IL-1β, and an increased level of IL-10 in colon tissue (all P<0.05).
|
30906449 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was lower anti-TNF use in EO-UC patients compared to AO-UC patients (5.8 vs 14.7%, p = 0.0091).
|
28884254 |
2017 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The highest levels of TNF-α were detected in the UC group.
|
21877213 |
2011 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
|
19286392 |
2009 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression levels of IgA and sIgA decreased, while IL-6, IL-8 and TNF-α further increased in the stress-treated UC mice (P<0.05).
|
30783488 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared to high dose corticosteroid use, anti TNF therapy is associated with less risk for death in Crohn's disease but no statistical difference in death outcomes in ulcerative colitis.
|
29535444 |
2018 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To describe the prevalence of serological markers in newly diagnosed treatment-naïve pediatric inflammatory bowel disease (IBD), their utility in differentiating Crohn's disease (CD), ulcerative colitis (UC) and symptomatic non-IBD patients and whether serological markers are associated with early TNF blocker treatment.
|
27887202 |
2017 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of TNF-α was observed in the colonic mucosa of children with CD and UC in comparison with controls.
|
26752469 |
2016 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because anti⁻tumor necrosis factor therapy is the mainstay for the treatment of moderate-to-severe inflammatory bowel disease; including Crohn's disease and ulcerative colitis, and because testosterone therapy in hypogonadal men with chronic inflammatory conditions reduce tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6, we suggest that testosterone therapy attenuates the inflammatory process and reduces the burden of disease by mechanisms inhibiting inflammatory cytokine expression and function.
|
30558178 |
2018 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CD and UC showed highly significant difference in the allelic distribution of TNF-α G-308A, where the A allele was found to be related to CD, and the G allele to UC.
|
26316104 |
2015 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Silencing of excessive secreted tumour necrosis factor (TNF)-α from macrophages might be an effective therapy of ulcerative colitis (UC), which acquires improvements on small interfering RNA (siRNA) delivery vectors.
|
26418829 |
2016 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This is the first time that the effect of original CS against UC in mice has been reported and it is through promoting dominant intestinal microflora such as <i>Blautia</i>, mitigating intestinal microflora dysbiosis, and regulating the expressions of TNF-α, claudin-1, occludin, and ZO-1.
|
31731793 |
2019 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The TNF-2 and LT alpha-2 haplotypes were associated with higher TNF alpha production in CD patients, and the TNF-4 haplotype was associated with lower TNF alpha production in UC patients.
|
11196710 |
2000 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015).
|
29774158 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
|
30054143 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis.
|
28837372 |
2018 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the impact of the single nucleotide polymorphisms of rs34436714 of the NOD-like receptor protein 12 gene on the production of tumor necrosis factor-alpha (TNFα) in patients with inflammatory bowel disease (IBD)In a matched case-control study 90 patients with IBD, 56 with Crohn disease (CD) and 34 with ulcerative colitis, were genotyped and compared to 98 healthy comparators matched for age and gender.
|
31169706 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Also, sensitivity analysis suggested a slightly reduced time from diagnosis to first tumor necrosis factor-α inhibitor treatment among familial CD and UC cases as compared with sporadic cases.
|
26288000 |
2015 |